Successful Treatment of Refractory Immune Thrombotic Thrombocytopenic Purpura with Daratumumab

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare life-threatening disease manifested by thrombocytopenia, microangiopathic hemolytic anemia, and impaired functions of organs and systems due to the thrombosis of small arteries. The basis of the disease lies in the production of autoantibodies that eliminate or inhibit the activity of metalloproteinase ADAMTS13 (A Disintegrin and Metalloprotease with ThromboSpondin type 1 repeats, member 13). ADAMTS13 is one of the plasma proteins that cleave the high-molecular-weight von Willebrand factor. The standard iTTP treatment includes therapeutic plasma exchange, caplacizumab administration, and immunosuppressive therapy with glucocorticoids and rituximab. The present paper documents the first case report in Russia demonstrating the effective use of daratumumab in a 51-year-old female patient with refractory iTTP. The disease manifested with hemolytic anemia and deep thrombocytopenia with pronounced neurological disorders. The ADAMTS13 activity was 0 %, ADAMTS13 inhibitor titer was 3 units by Bethesda. As a result of the standard triplet therapy followed by addition of bortezomib, the thrombocyte count returned to normal, hemolysis ceased, and neurological symptoms regressed. At the same time, the hematological analysis showed zero activity of ADAMTS13 as well as persistent plasma protein inhibitor. The absence of this inhibitor and an increase of ADAMTS13 activity to 45 %, which correspond to complete iTTP remission, were achieved only after daratumumab administration. The paper comprehensively discusses the central features of the clinical case report and possible action mechanisms of various drugs used for the treatment of this life-threatening disease.

• E.E. Klebanova National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0002-8141-9422 (unauthenticated)
• Gennadii Martinovich Galstyan National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0001-8818-8949 (unauthenticated)
• S.Yu. Mamleeva National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0003-1492-1735 (unauthenticated)
• D.K. Bessmertnyy National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0001-5905-7237 (unauthenticated)
• Z.T. Fidarova National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0003-0934-6094 (unauthenticated)
• E.N. Parovichnikova National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0001-6177-3566 (unauthenticated)

1. Coppo P, Bubenheim M, Azoulay E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733–42. doi: 10.1182/blood.2020008021. DOI: https://doi.org/10.1182/blood.2020008021
2. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511–22. doi: 10.1056/NEJMoa1505533. DOI: https://doi.org/10.1056/NEJMoa1505533
3. Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380(4):335–46. doi: 10.1056/nejmoa1806311. DOI: https://doi.org/10.1056/NEJMoa1806311
4. Knoebl P, Cataland S, Peyvandi F, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479–84. doi: 10.1111/jth.14679. DOI: https://doi.org/10.1111/jth.14679
5. Galstyan GM, Klebanova E, Mamleeva S, et al. Tailored Treatment of Immune Thrombotic Thrombocytopenic Purpura. Semin Thromb Hemost. 2024:18–21. doi: 10.1055/s-0044-1791780. DOI: https://doi.org/10.1055/s-0044-1791780
6. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–53. doi: 10.1182/blood-2011-03-341131. DOI: https://doi.org/10.1182/blood-2011-03-341131
7. Галстян Г.М., Налбандян С.А., Двирнык В.Н. и др. Ложное определение количества тромбоцитов крови при внутрисосудистом гемолизе. Анестезиология и реаниматология. 2019;(4):61–7. doi: 10.17116/anaesthesiology201904161. [Galstyan G.M., Nalbandyan S.A., Dvirnyk V.N., et al. Spuriously high platelet counts caused by intravascular haemolysis. Russian Journal of Anesthesiology and Reanimatology. 2019;(4):61‑7. doi: 10.17116/anaesthesiology201904161. (In Russ)] DOI: https://doi.org/10.17116/anaesthesiology201904161
8. Долгов В.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. М. — Тверь: Триада, 2005. 227 с. [Dolgov V.V., Svirin P.V. Laboratornaya diagnostika narushenii gemostaza. (Laboratory diagnosis of hemostasis disorders.) Moscow-Tver: Triada Publ.; 2005. 227 p. (In Russ)]
9. Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: Current strategies for investigation and management. Br J Haematol. 2008;143(1):16–26. doi: 10.1111/j.1365-2141.2008.07275.x. DOI: https://doi.org/10.1111/j.1365-2141.2008.07275.x
10. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. doi: 10.1111/jth.13571. DOI: https://doi.org/10.1111/jth.13571
11. Cuker A, Cataland SR, Coppo P, et al. Redefining Outcomes in Immune TTP: an International Working Group Consensus Report. Blood. 2021;137(14):1855–61. doi: 10.1182/blood.2020009150. DOI: https://doi.org/10.1182/blood.2020009150
12. Lee NCJ, Yates S, Rambally S, et al. Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single-centre retrospective cohort and systematic literature review. Br J Haematol. 2024;204(2):638–43. doi: 10.1111/bjh.19035. DOI: https://doi.org/10.1111/bjh.19035
13. Maschan A, Petrova U, Kalinina I, et al. Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases. Pediatr Blood Cancer. 2021;68(4):e28818. doi: 10.1002/PBC.28818. DOI: https://doi.org/10.1002/pbc.28818
14. Katodritou E, Kastritis E, Dalampira D, et al. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group. Am J Hematol. 2023;98(5):730–8. doi: 10.1002/ajh.26891. DOI: https://doi.org/10.1002/ajh.26891
15. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. New Engl J Med. 2016;375(8):754–66. doi: 10.1056/nejmoa1606038. DOI: https://doi.org/10.1056/NEJMoa1606038
16. Tang W, Zhang L, Zheng Y, et al. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review. Front Oncol. 2024;14:1286029. doi: 10.3389/fonc.2024.1286029. DOI: https://doi.org/10.3389/fonc.2024.1286029
17. Van den Berg J, Hovinga JAK, Pfleger C, et al. Daratumumab for immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6(3):993–7. doi: 10.1182/bloodadvances.2021005124. DOI: https://doi.org/10.1182/bloodadvances.2021005124
18. Aggarwal A, White D, Pavord S, et al. Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura. Br J Haematol. 2023;202(2):429–33. doi: 10.1111/bjh.18854. DOI: https://doi.org/10.1111/bjh.18854
19. Tran TB, Boyce J, Mitchell H, et al. Real-world Experience of Caplacizumab for Adolescents in the First-line Setting: Case Reports. J Pediatr Hematol Oncol. 2023;45(8):E1031–4. doi: 10.1097/MPH.0000000000002716. DOI: https://doi.org/10.1097/MPH.0000000000002716
20. Djulbegovic M, Tong J, Xu A, et al. Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood Adv. 2023;7(10):2132–42. doi: 10.1182/bloodadvances.2022008443. DOI: https://doi.org/10.1182/bloodadvances.2022008443
21. Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2018;3(1):26–37. doi: 10.1002/RTH2.12160. DOI: https://doi.org/10.1002/rth2.12160
22. Mazepa M, Masias C, Chaturvedi S. How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood. 2019;134(5):415–20. DOI: https://doi.org/10.1182/blood.2019000954
23. Клебанова Е.Е., Галстян Г.М., Мамлеева С.Ю. и др. Способ лечения приобретенной тромботической тромбоцитопенической пурпуры, основанный на достижении целевых показателей активности ADAMTS13 в плазме крови. Патент № 2813436С1 от 02.12.2024. [Klebanova E.E., Galstyan G.M., Mamleeva S.Yu. et al. Sposob lecheniya priobretennoi tromboticheskoi trombotsitopenicheskoi purpury, osnovannyi na dostizhenii tselevykh pokazatelei aktivnosti ADAMTS13 v plazme krovi. (Treatment method for acquired thrombotic thrombocytopenic purpura based on achieving plasma ADAMTS13 activity targets.) Patent No. 2813436С1 dated 02.12.2024. (In Russ)]
24. Yates SG, Hofmann SL, Ibrahim IF, et al. Tailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpura. Blood VTH. 2024;1(3):100010. doi: 10.1016/j.bvth.2024.100010. DOI: https://doi.org/10.1016/j.bvth.2024.100010